Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward [Seeking Alpha]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Seeking Alpha
LXRX plans to resubmit ZYNQUISTA's NDA in 2026, contingent on positive safety data from the ongoing STENO1 study. Positive FDA feedback enables pilavapadin to advance into two short, registrational Phase 3 studies for diabetic peripheral neuropathic pain (DPNP). Strong cash position ($125.2M) and potential milestone payments provide runway into 2027, but execution and regulatory risks remain material. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » CHARTCHAI KANTHATHAN/iStock via Getty Images The last time I spoke about Lexicon Pharmaceuticals, Inc. LXRX) it was with respect to a Seeking Alpha article entitled " Advisory Panel Votes In Split Fashion For Lexicon's Drug: What does More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private PlacementGlobeNewswire
- Lexicon Announces Proposed Public Offering of Common StockGlobeNewswire
- How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th AnniversaryGlobeNewswire
LXRX
Earnings
- 11/6/25 - Beat
LXRX
Sec Filings
- 1/30/26 - Form FWP
- 1/30/26 - Form FWP
- 1/29/26 - Form 8-K
- LXRX's page on the SEC website